These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1686 related items for PubMed ID: 28698142

  • 1. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J, Lai W, Li Q, Yu Y, Jin J, Guo W, Zhou X, Liu X, Wang Y.
    Biochem Biophys Res Commun; 2017 Sep 16; 491(2):469-477. PubMed ID: 28698142
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G, Lei W, Wang S, Xiao R, Guo K, Xia Y, Zhou X, Zhang K, Liu X, Wang Y.
    J Cancer Res Clin Oncol; 2012 Apr 16; 138(4):657-70. PubMed ID: 22237452
    [Abstract] [Full Text] [Related]

  • 3. An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model.
    Wang Y, Huang P, Hu Y, Guo K, Jia X, Huang B, Liu X, He X, Huang F.
    Acta Biochim Biophys Sin (Shanghai); 2021 May 26; 53(6):766-774. PubMed ID: 33928346
    [Abstract] [Full Text] [Related]

  • 4. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
    Lei W, Liu HB, Wang SB, Zhou XM, Zheng SD, Guo KN, Ma BY, Xia YL, Tan WS, Liu XY, Wang YG.
    Acta Pharmacol Sin; 2013 Apr 26; 34(4):531-40. PubMed ID: 23503473
    [Abstract] [Full Text] [Related]

  • 5. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
    Yuan X, Zhang Q, Li Z, Zhang X, Bao S, Fan D, Ru Y, Dong S, Zhang Y, Zhang Y, Ye Z, Xiong D.
    Cancer Lett; 2016 Oct 10; 381(1):85-95. PubMed ID: 27450327
    [Abstract] [Full Text] [Related]

  • 6. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y, Liu T, Huang P, Zhao H, Zhang R, Ma B, Chen K, Huang F, Zhou X, Cui C, Liu X.
    Oncotarget; 2015 May 30; 6(15):13564-78. PubMed ID: 25980438
    [Abstract] [Full Text] [Related]

  • 7. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN, Huang WD, Cai Y, Ding M, Gu JF, Wei N, Sun LY, Cao X, Li HG, Zhang KJ, Liu XR, Liu XY.
    Mol Cancer; 2011 Nov 01; 10():133. PubMed ID: 22040050
    [Abstract] [Full Text] [Related]

  • 8. Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and apoptosis promotion.
    Xie W, Hao J, Zhang K, Fang X, Liu X.
    Biochem Biophys Res Commun; 2018 Sep 18; 503(4):2758-2763. PubMed ID: 30119884
    [Abstract] [Full Text] [Related]

  • 9. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H, Wei F, Li H, Ji X, Li S, Chen X.
    Int J Mol Med; 2013 Feb 18; 31(2):377-85. PubMed ID: 23229955
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
    Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F, Milazzo M, Altavilla G, Giacomelli L, Fornari F, Hemminki A, Di Virgilio F, Gramantieri L, Negrini M, Sabbioni S.
    PLoS One; 2013 Feb 18; 8(9):e73964. PubMed ID: 24069256
    [Abstract] [Full Text] [Related]

  • 11. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y, Zhu Y, Huang X, Ai K, Zheng Q, Yuan Z.
    Int J Oncol; 2015 Aug 18; 47(2):668-78. PubMed ID: 26081241
    [Abstract] [Full Text] [Related]

  • 12. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, Yoshida R, Uno F, Mizuguchi H, Ohtsuru A, Urata Y, Kagawa S, Fujiwara T.
    Eur J Cancer; 2012 Sep 18; 48(14):2282-91. PubMed ID: 22244827
    [Abstract] [Full Text] [Related]

  • 13. Targeting gene-virus-mediated manganese superoxide dismutase effectively suppresses tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Huang F, Ma B, Wang Y, Xiao R, Kong Y, Zhou X, Xia D.
    Cancer Biother Radiopharm; 2014 Dec 18; 29(10):403-11. PubMed ID: 25414976
    [Abstract] [Full Text] [Related]

  • 14. GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells.
    Zhang X, Meng S, Zhang R, Ma B, Liu T, Yang Y, Xie W, Liu X, Huang F, Liu T, Zhou X, Liu X, Wang Y.
    Oncotarget; 2016 May 17; 7(20):29346-58. PubMed ID: 27121064
    [Abstract] [Full Text] [Related]

  • 15. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ, Zhang J, Wu YM, Qian J, Liu XJ, Yan LC, Zhou XM, Xiao RJ, Wang YG, Cao X, Wei N, Liu XR, Tang B, Jiao XY, Chen K, Liu XY.
    Cancer Gene Ther; 2012 Sep 17; 19(9):619-29. PubMed ID: 22790965
    [Abstract] [Full Text] [Related]

  • 16. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
    El-Shemi AG, Ashshi AM, Na Y, Li Y, Basalamah M, Al-Allaf FA, Oh E, Jung BK, Yun CO.
    J Exp Clin Cancer Res; 2016 May 06; 35():74. PubMed ID: 27154307
    [Abstract] [Full Text] [Related]

  • 17. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY.
    Cancer Biol Ther; 2010 Aug 01; 10(3):242-50. PubMed ID: 20574150
    [Abstract] [Full Text] [Related]

  • 18. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC, Cao X, Gui JH, Zhou XM, Zhong D, Yan QL, Huang WD, Qian QJ, Zhao FL, Liu XY.
    Hum Gene Ther; 2011 Sep 01; 22(9):1109-19. PubMed ID: 21361790
    [Abstract] [Full Text] [Related]

  • 19. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C, Homicsko K, Lukashev AN, Pittet AL, Iggo RD.
    BMC Cancer; 2006 Oct 04; 6():236. PubMed ID: 17020613
    [Abstract] [Full Text] [Related]

  • 20. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X, Cao X, Wei R, Cai Y, Li H, Gui J, Zhong D, Liu XY, Huang K.
    Cancer Gene Ther; 2012 Jan 04; 19(1):49-57. PubMed ID: 21979578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 85.